Skip to content
Screener

Candel Therapeutics, Inc. CADL Operating Lease ROU Assets

Operating Lease ROU Assets at other companies

Replimune Group logo
Replimune GroupREPL
10.4%+0.1pp
CG Oncology logo
CG OncologyCGON
$5.73M+494%
Regenxbio logo
RegenxbioRGNX
$43.87M-13.1%
Precigen logo
PrecigenPGEN
11.4%-0.1pp
uniQure logo
uniQureQURE
$11.61M-14.9%
Sana Biotechnology logo
Sana BiotechnologySANA
$35.85M-34.6%

Other financials

Income statement

See full
Revenue$31.0K0.0%
Operating income-$16.3M-100%
Net income-$8.9M-220%
EPS (diluted)-$0.14-208%

Balance sheet

See full
Cash & equivalents$194.8M+111%
Total debt$2.8M-73.9%
Total equity$138.0M+84.8%
Total assets$201.9M+111%

Cash flow

See full
Operating cash flow-$18.0M-109%
CapEx$675.0K+22,400%
Free cash flow-$18.7M-117%

Valuation

See full
Market cap$769.34M+155%
Enterprise value$577.35M+176%

Profitability

See full
Operating margin-28,000.8%+15,050pp
Net margin-15,156.5%-5,064pp
FCF margin-26,383.9%+14,851pp

Returns & leverage

See full
Return on equity-51.2%-16.6pp
Debt / equity-0.1×
Current ratio28×+23.4×

Where this comes from

Reported directly by Candel Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The source filing: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026.

Filed
May 14, 2026, 8:30 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-222904
Line itemMARCH 31,2026(Unaudited)DECEMBER 31,2025
Prepaid expenses and other current assets2,9181,658
Total current assets197,752121,389
Fixed assets, net2,0751,642
Lease right of use assets1,5691,661
Restricted cash416416
Other assets10887
Total assets$201,920$125,195
Liabilities and Stockholders’ Equity

Item 1. Financial Statements.

FAQ

What is Candel Therapeutics, Inc.'s operating lease ROU assets?
Candel Therapeutics, Inc. (CADL) reported operating lease ROU assets of $1.57M in Q1 2026.
How has Candel Therapeutics, Inc.'s operating lease ROU assets changed year-over-year?
Candel Therapeutics, Inc.'s operating lease ROU assets increased by 235.3% year-over-year, from $468K to $1.57M.
What is the long-term trend for Candel Therapeutics, Inc.'s operating lease ROU assets?
Over 3 years (2022 to 2025), Candel Therapeutics, Inc.'s operating lease ROU assets has grown at a 16.3% compound annual growth rate (CAGR), from $1.06M to $1.66M.
What does operating lease ROU assets mean?
Right-of-use assets representing the lessee's right to use leased property over the lease term under ASC 842 operating lease classification.

Ask your AI about Candel Therapeutics, Inc.'s operating lease rou assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude